Abstract: Ｏｂｊｅｃｔｉｖｅ：To observe the efficacy and safety of Roxadustat in treatment of renal anemia in peritoneal dialysis(PD) patients.
Ｍｅｔｈｏｄｏｌｏｇｙ：PD patients with renal anemia who were treated with Roxadustat(Roxadustat group) recruited from June 2019 to February 2020 were retrospectively analyzed. PD patients who were treated with recombinant human erythropoietin(rHuEPO) by subcutaneous injection therapy were randomly enrolled in a 1∶1 ratio as control group. Clinical characteristics, hemoglobin(Hb), iron metabolism index, inflammatory index, lipid metabolism index and adverse events in the two groups were analyzed. All patients were completely followed up for at least 1 year.
Ｒｅｓｕｌｔｓ：A total of 34 PD patients in roxadustat group and 34 PD patients in rHuEPO group were collected. There were no significant differences in baseline clinical data and laboratory values between the two groups. The baseline Hb in Roxadustat group was 853±114 g／L.Drug doses were adjusted to reach a Hb level of 110 to 120 g per liter in both groups. After 1 year of treatment, Hb in both groups was significantly higher than the baseline value.There was no significant difference in Hb levels between the two groups after 1year treatment(P=0081). However, compared with control group, Roxadustat group had improved iron metabolism, lipid metabolism and inflammation indexes, better MAP and fasting blood glucose.Compared with the baseline, serum iron, transferrin safuration (TSAT) and ferritin decreased, total ironbinding capacity increased after 1year of Roxadustat treatment (P<005). There was no significance in Hb between different inflammatory indexes based on CRP levels in Roxadustat group, but it had a less increase of Hb among patients with elevated CRP levels in control group (P<005). The incidence of elevated blood pressure in Roxadustat group was lower than that in control group (0 vs 235％, P=0005).
Ｃｏｎｃｌｕｓｉｏｎ：Roxadustat effectively corrected anemia not less than rHuEPO in PD patients, and improved iron metabolism, lipid metabolism,glycometabolism and inflammatory indexes. Inflammation state did not affect the efficacy of Roxadustat. Therefore, Roxadustat has good efficacy and safety in PD patients.

Key words: Roxadustat, peritoneal dialysis, renal anemia, iron metabolism, inflammatory index